EWTX
NASDAQEdgewise Therapeutics Inc.
News · 26 weeks60+150%
2026-04-192026-10-11
Mix2490d
- Insider12(50%)
- Other7(29%)
- SEC Filings3(13%)
- Earnings1(4%)
- Analyst1(4%)
Latest news
25 items- ANALYSTWilliam Blair initiated coverage on Edgewise TherapeuticsWilliam Blair initiated coverage of Edgewise Therapeutics with a rating of Outperform
- PREdgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400– Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% –– EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human data to be presented at HFSA 2026 –BOULDER, Colo., Oct. 8, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiometabolic diseases, today announced the dosing of the first patient in EQUINOX-HFpEF, a Phase 2 clinical trial evaluating EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction (HFpEF) who have a left ventricular ejection fraction (LVEF) of at least 50%.EDG-15400 is an investigational, oral, selective cardiac sarc
- INSIDERDirector Fox Jonathan C was granted 308 shares, increasing direct ownership by 1% to 25,141 units (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- PREdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesBOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on September 30, 2026, Edgewise granted inducement stock options to purchase a total of 7,500 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 3,751 shares of Edgewise's common stock to 3 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). Each inducement stock option has an ex
- PREdgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500- The MoA that targets the Regulatory Light Chain (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve -- Company to host webcast to discuss these findings today at 8:30 a.m. Eastern Time -BOULDER, Colo., Sept. 22, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that it will host an investor conference call to discuss the preclinical pharmacologic profile of EDG-7500, a first-in-class cardiac sarcomere modulator targeting the RLC. Data will be provided supporting EDG-7500's ability to improve cardiac relax
- PREdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesBOULDER, Colo., Sept. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on August 31, 2026, Edgewise granted inducement stock options to purchase a total of 21,000 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 10,501 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
- PREdgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –BOULDER, Colo., Aug. 24, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation in symptomatic HCM while
- INSIDERAmendment: SEC Form 4 filed by Chief Financial Officer Nofi Michael4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by CMO Donovan Joanne M.4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Scientific Officer Russell Alan J4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by General Counsel Moore John R4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Business Officer Derakhshan Behrad4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Nofi Michael4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERGeneral Counsel Moore John R converted options into 12,499 shares and sold $219,823 worth of shares (5,016 units at $43.82), increasing direct ownership by 73% to 17,697 units (SEC Form 4) (for tax liability)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERCMO Donovan Joanne M. converted options into 12,812 shares and sold $412,703 worth of shares (9,441 units at $43.71) as part of a pre-agreed trading plan, increasing direct ownership by 64% to 8,625 units (SEC Form 4) (for tax liability)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERChief Scientific Officer Russell Alan J converted options into 12,812 shares and sold $258,042 worth of shares (5,901 units at $43.73), increasing direct ownership by 28% to 31,466 units (SEC Form 4) to satisfy withholding obligation4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERChief Business Officer Derakhshan Behrad converted options into 13,281 shares and sold $223,424 worth of shares (5,100 units at $43.81), increasing direct ownership by 35% to 31,826 units (SEC Form 4) to cover taxes4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERPresident and CEO Koch Kevin converted options into 39,844 shares and sold $785,042 worth of shares (17,971 units at $43.68), increasing direct ownership by 71% to 52,488 units (SEC Form 4) (withholding obligation)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Edgewise Therapeutics Inc.SCHEDULE 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)
- SECSEC Form 144 filed by Edgewise Therapeutics Inc.144 - Edgewise Therapeutics, Inc. (0001710072) (Subject)
- SECSEC Form SCHEDULE 13G filed by Edgewise Therapeutics Inc.SCHEDULE 13G - Edgewise Therapeutics, Inc. (0001710072) (Subject)
- SECEdgewise Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)
- SECSEC Form 10-Q filed by Edgewise Therapeutics Inc.10-Q - Edgewise Therapeutics, Inc. (0001710072) (Filer)
- PREdgewise Therapeutics Reports Second Quarter 2026 Financial Results– Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –– Completed sale of sevasemten and muscular dystrophy business to Servier for up to $2.65 billion in July 2026, strengthening the balance sheet, sharpening focus on the cardiovascular pipeline –BOULDER, Colo., Aug. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026 and recent business highlights. "In the seco
- INSIDERSEC Form 4 filed by Director Root Jonathan D4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
EWTX FAQ
7 questionsWhat does Edgewise Therapeutics Inc. do?
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.Where does EWTX stock trade?
Edgewise Therapeutics Inc. (EWTX) is listed on NASDAQ.What sector and industry is EWTX in?
Edgewise Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Edgewise Therapeutics Inc. go public?
Edgewise Therapeutics Inc. (EWTX) completed its IPO in 2021.What are analysts saying about EWTX?
Edgewise Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-10-16. Recent price targets range from $1400.00 to $4600.00.What companies are similar to EWTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare EWTX side-by-side with any of them on Quantisnow.How can I track EWTX on Quantisnow?
Quantisnow aggregates Edgewise Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EWTX to receive live email and push alerts on every new disclosure.